Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Holdings Increased by State of Alaska Department of Revenue

State of Alaska Department of Revenue lifted its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 33.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 202,441 shares of the company's stock after buying an additional 50,199 shares during the quarter. State of Alaska Department of Revenue owned 0.15% of Vir Biotechnology worth $1,485,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of VIR. State Street Corp grew its stake in Vir Biotechnology by 10.4% during the 3rd quarter. State Street Corp now owns 5,625,533 shares of the company's stock valued at $42,135,000 after purchasing an additional 530,645 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Vir Biotechnology by 13.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company's stock valued at $8,496,000 after purchasing an additional 136,087 shares in the last quarter. Barclays PLC grew its stake in Vir Biotechnology by 1.3% during the 3rd quarter. Barclays PLC now owns 550,186 shares of the company's stock valued at $4,121,000 after purchasing an additional 7,287 shares in the last quarter. abrdn plc acquired a new stake in Vir Biotechnology during the 4th quarter valued at approximately $2,666,000. Finally, Jacobs Levy Equity Management Inc. grew its stake in Vir Biotechnology by 10.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 350,265 shares of the company's stock valued at $2,623,000 after purchasing an additional 33,473 shares in the last quarter. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Vir Biotechnology

In related news, Director Vicki L. Sato sold 10,960 shares of the business's stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total transaction of $137,219.20. Following the completion of the transaction, the director now owns 1,312,391 shares in the company, valued at $16,431,135.32. The trade was a 0.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 12,598 shares of company stock worth $152,136 in the last 90 days. 15.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Morgan Stanley upgraded Vir Biotechnology from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. Needham & Company LLC restated a "buy" rating and set a $19.00 price objective on shares of Vir Biotechnology in a research note on Wednesday, November 20th. HC Wainwright restated a "buy" rating and set a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, January 31st. JPMorgan Chase & Co. lifted their target price on Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a research report on Thursday, January 9th. Finally, Leerink Partners lifted their target price on Vir Biotechnology from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $34.83.

Vir Biotechnology Stock Up 0.7 %

Shares of VIR traded up $0.07 during mid-day trading on Friday, hitting $9.65. The stock had a trading volume of 862,734 shares, compared to its average volume of 1,819,804. Vir Biotechnology, Inc. has a fifty-two week low of $6.56 and a fifty-two week high of $14.45. The company has a market cap of $1.33 billion, a PE ratio of -2.46 and a beta of 0.64. The company's fifty day simple moving average is $9.13 and its two-hundred day simple moving average is $8.46.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).